Skip to main content
. 2016 May 18;12:209–218. doi: 10.2147/VHRM.S100293

Figure 1.

Figure 1

Incidences of symptomatic thromboembolic events and treatment-emergent major bleeding events by timing of first dose of prophylactic therapy.

Notes: (A) Rivaroxaban. (B) Standard of care. *95% confidence interval. Results are presented for the safety population (patients who received at least one dose of rivaroxaban or SOC).

Abbreviations: EMA, European Medicines Agency; SOC, standard of care.